Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2026)

Fulcrum Therapeutics (FULC) has 5 years of Operating Leases data on file, last reported at $3.4 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 41.94% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 41.94% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 37.31% from the prior year.
• Operating Leases for Q1 2026 stood at $3.4 million, down from $4.0 million in the prior quarter.
• Over the last five years, Operating Leases for FULC reached as high as $12.8 million in Q1 2022 and fell as low as $3.4 million in Q1 2026.
• Historically, Operating Leases has averaged $8.1 million across 5 years, with a median of $8.1 million in 2024.
• Across the five-year window, Operating Leases retreated 20.05% in 2024 and slumped 41.94% in 2026, its largest moves.
• Year by year, Operating Leases stood at $10.8 million in 2022, then dropped by 20.26% to $8.6 million in 2023, then dropped by 25.33% to $6.4 million in 2024, then plunged by 37.31% to $4.0 million in 2025, then fell by 15.67% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $3.4 million in Q1 2026, $4.0 million in Q4 2025, and $4.7 million in Q3 2025.